ResearchPod Summary
SURF1-related Leigh syndrome is a severe, early-onset mitochondrial disorder caused by defects in the assembly of mitochondrial complex IV. While initial gene replacement therapy attempts successfully restored enzyme activity in mice, subsequent safety evaluations revealed significant, dose-independent cytotoxicity in rats. This paper investigates whether high levels of SURF1 protein, driven by strong promoters, caused this toxicity and attempts to engineer a safer, yet equally effective, therapeutic vector.
The researchers hypothesized that the previously observed cytotoxicity was a direct result of SURF1 protein overexpression driven by a strong ubiquitous promoter (CBh). To test this, they engineered new gene therapy constructs utilizing weaker promoters (JeT and JeTI) and a synthetic polyadenylation sequence to downregulate transgene expression. These new designs were tested for efficacy in restoring complex IV (COX) activity in patient-derived fibroblasts and in a Surf1 knockout (KO) mouse model, and for safety in wild-type rats.
The researchers found that the original high-expression vector caused significant histopathological damage in the heart and dorsal root ganglia of rats. The new vector designs (JeTI-hSURF1v2) significantly reduced SURF1 protein expression compared to the original design, yet still achieved similar levels of complex IV restoration in patient cells and in the CNS/peripheral tissues of KO mice. Furthermore, these optimized constructs were well-tolerated in rats and restored exercise capacity and corrected lactate acidosis in treated mice, proving that lower, more controlled protein expression is sufficient for therapeutic benefit without the associated toxic risks.
This study illustrates the 'Goldilocks' problem in gene therapy for mitochondrial disorders: insufficient expression fails to treat the disease, while excessive expression can induce deleterious cellular stress and organ toxicity. By fine-tuning the regulatory elements of the transgene, the authors have successfully mitigated the toxicity risks that would have otherwise prevented the advancement of this treatment toward clinical trials.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.